Erratum: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma (Kidney Cancer (2022) 6 (69–79) DOI: 10.3233/KCA-210117)

Akanksha Sharma, Roy Elias, Alana Christie, Noelle S. Williams, Ivan Pedrosa, Georg A. Bjarnason, James Brugarolas

Research output: Contribution to journalComment/debatepeer-review

Abstract

On page 77, The Funding statement should mention grant code R21CA263264 and be as follows: “FUNDING This researchwas supported by theUTSWKidney Cancer SPORE grant P50CA196516 (J.B. and I.P.) and NIH grant R21CA263264 (J.B.). R. Elias receives support from an institutional award from the BurroughsWellcome Fund.

Original languageEnglish (US)
Pages (from-to)15
Number of pages1
JournalKidney Cancer
Volume7
Issue number1
DOIs
StatePublished - 2023

ASJC Scopus subject areas

  • Oncology
  • Nephrology

Fingerprint

Dive into the research topics of 'Erratum: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma (Kidney Cancer (2022) 6 (69–79) DOI: 10.3233/KCA-210117)'. Together they form a unique fingerprint.

Cite this